Citizens analyst Jonathan Wolleben reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market O

BlackRock Inc. purchased a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) in the undefined

Deutsche Bank AG acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) in the second

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq L

TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers

RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform a

MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel g

Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Ou

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MI

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript

Mirum Pharmaceuticals NASDAQ: MIRM reported second-quarter net product sales of $176 million and rai

The headline numbers for Mirum Pharmaceuticals (MIRM) give insight into how the company performed in

Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.8 per share versus the Zacks

Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.80) per share which missed the

Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday&

Mirum Pharmaceuticals (NASDAQ:MIRM) raises FY2026 sales outlook from $660.000 million-$680.000 milli

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Re

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Second Quarter 2026 Financia

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq L

RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform a

Mirum Pharmaceuticals is evolving into a leading liver disease franchise, with robust revenue growth

JP Morgan analyst Jessica Fye maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and

Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being high

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs

Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begin

Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begin

Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begin

Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Ou

- Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic oss

Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 r

FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum Pharmaceuticals and Incyte Announce P

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq L

Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweigh

The late-breaking rapid-fire presentation will include results from Cohort 1 of the placebo-controll

Citigroup analyst Yigal Nochomovitz initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) wit

Wall Street analysts changed ratings on top names. Check our analyst ratings page for full updates.

Top Wall Street analysts upgraded STUB, PGNY, AMT, and BAP stocks and raised their price targets. Se

Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analyst

Wolfe Research analyst Kalpit Patel initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) wit

Miram Pharmaceuticals to offer, subject to market conditions and other factors, $600.0 million aggre

TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises

RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform a

Evercore ISI Group analyst Gavin Clark-Gartner maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with

Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and r

Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.50) per share which missed the

Mirum Pharmaceuticals (NASDAQ:MIRM) raises FY2026 sales outlook from $630.000 million-$650.000 milli

Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweigh

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MI

Mirum stock rises after Phase 2b VISTAS data for volixibat; AZURE-1 results and technical levels hig